The growth of Viagra and its effect on the drug landscape presents a complex question for traders. While the early sales data were remarkable, the intellectual property has expired, leading to a wave of copycat alternatives that are reducing revenue. Moreover, the market is facing issues related to demographic trends and evolving healthcare guideli